Altasciences is a mid-size CRO based in Quebec, Canada, that focuses on providing comprehensive early-stage drug development, going from lead candidate selection to proof of concept. Alliance Contract Pharma, based in Harleysville, PA, offers contract manufacturing of small-molecule products, as well as a range of analytical services.
By acquiring Alliance Contract Pharma, the company will add commercial manufacturing, GMP warehouse storage, and clinical supply distribution to its range of preclinical, clinical, and bioanalytical offerings.
Chris Perkin, CEO of Altasciences, said the acquisition will enable his company to offer a larger, more comprehensive range of services to its contract customers.
“We remain committed to providing our clients with value-added services that create a new paradigm of drug development outsourcing,” he said.
According to the company, sending data, projects, and/or methodologies between CROs, or among divisions within a large CRO, can be time-consuming and error-prone, and the process can lead to extended delays.
The company has recently executed a number of strategic acquisitions. These include the integration of their preclinical business in 2018, and now the purchase of Alliance Contract Pharma. Additionally, in February 2019, the company brought various divisions together and consolidated.
Alliance Contract Pharma president Stephen Schweibenz said the deal offers opportunities for both companies.
“We are excited to be joining a team that is responsive and understanding, and continuously looking to create innovative partnerships that redefine the status quo and address the challenges that our clients face in meeting critical milestones,” Schweibenz said.
